Browse studies

Find your next paid study

13 recruiting studies matching your filters

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients wi…

Urothelial CancerUrinary Bladder Neoplasms

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07566156

Phase 2

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the…

Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06833073

Phase 3

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or…

Non-Muscle Invasive Bladder Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06919965

Phase 3

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of in…

Non-Muscle Invasive Bladder Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06319820

A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer …

Non-Muscle Invasive Bladder Neoplasms

Estimated

~$10 – $1,050

Janssen Research & Development, LLCNCT07309445

Phase 3

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer t…

Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07218380

Phase 2

FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMI…

Urinary Bladder NeoplasmsUrologic NeoplasmsReceptor, Fibroblast Growth Factor, Type 3

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07827612

Observational

A Pilot Study Using Hyperthermic Irrigation Followed by Intravesical Chemotherapy in Patients With Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer

The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-mus…

Bladder CancerBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Non-muscle Invasive Bladder Cancer (NMIBC)+6 more

Estimated

~$10 – $6,250

CAMC Health SystemNCT07817173

Phase 1

Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of t…

Bladder CancerUrinary Bladder Neoplasms

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07222488

Phase 1

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other m…

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT05614739

Phase 1

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe f…

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more

Estimated

~$10 – $8,750

Seagen, a wholly owned subsidiary of PfizerNCT04389632

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney

The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bl…

Urothelial CancerCancerBladder Neoplasms+1 more

Estimated

~$10 – $750

Lahey ClinicNCT00872495